Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802) (2009)
Katsumata, N.,
Watanabe, T.,
Minami, H.,
Aogi, K.,
Tabei, T.,
Sano, M.,
...
Background: This randomized, multicenter, phase III trial compared doxorubicin plus cyclophosphamide (AC), single-agent docetaxel (D), and an alternating regimen of AC and docetaxel (AC–D) as...
Evaluation of the safety and tolerability of oral TAS-108 in postmenopausal patients with metastatic breast cancer (2009)
Saeki, T.,
Noguchi, S.,
Aogi, K.,
Inaji, H.,
Tabei, T.,
Ikeda, T.
Background: The potential of TAS-108 for the treatment of breast cancer has been shown by preclinical studies. We therefore investigated the safe dosage, tolerability, and effectiveness on hormone...
A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy (2009)
Segawa, Y.,
Aogi, K.,
Inoue, K.,
Sano, M.,
Sekine, I.,
Tokuda, Y.,
...
Background: The 5-HT3 receptor antagonists (RAs) help maintain the standard of care, in various combinations with other agents, for prevention of chemotherapy-induced nausea and vomiting (CINV)....
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials (2005)
ABE, O,
ABE, R,
ENOMOTO, K,
KIKUCHI, K,
KOYAMA, H,
MASUDA, H,
...
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005)
ABE, O,
ABE, R,
ENOMOTO, K,
KIKUCHI, K,
KOYAMA, H,
MASUDA, H,
...